FDA Approves Gilead's New Single Tablet HIV Regimen
The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologically suppressed adults treating HIV.
Gilead got permission from the government to sell a new HIV medicine that people only take once a day instead of multiple pills. This shows the company keeps making useful new medicines, which could help its business grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.